



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Bastian Nuyen et al. Art Unit : 1655
Serial No. : 09/622,433 Examiner : Randall O. Winston
Filed : May 10, 2002 Conf. No. : 4574
Title : PHARMACEUTICAL FORMULATION OF A DIDEMNIN COMPOUND

MAIL STOP RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form.

The listed references were cited in connection with related, copending USSN 10/130,097 ("the '097 application"). The '097 application was listed on Applicants' Information Disclosure Statement filed on October 18, 2004.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

June 26, 2006

Date of Deposit

Signature

Jennifer Robins

Typed or Printed Name of Person Signing Certificate


Applicant : Bastian Nuyen et al.
Serial No. : 09/622,433
Filed : May 10, 2002
Page : 2 of 2

Attorney's Docket No.: 14620-
012US1 / JC/USP278531

No fee is believed due as this Statement is being filed concurrently with a Request for Continued Examination under 37 C.F.R. 1.114. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No.: 14620-012US1.

Respectfully submitted,

Date: June 26, 2006



John T. Kendall, Ph.D.
Reg. No. 50,680

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14620-012US1	Application No. 09/622,433
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Bastian Nuyen et al.	
		Filing Date May 10, 2002	Group Art Unit 1655



Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AA	Hudes, G.R., "Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer", <u>J. Clin Oncol.</u> , 15(9):3156-63 (1997).
	AB	Matsuoka, M., "Comparison of the effects of l-carnitine, d-carnitine and acetyl-l-carnitine on the neurotoxicity of ammonia", <u>Biochemical Pharmacology</u> , (46(1):159-164 (1993).
	AC	Mead Johnson Oncology Products, Taxol (Paclitaxel) Injection Labeling Revision (04/09/98).
	AD	Rinehart, K., "Antitumor compounds from tunicates", <u>Medicinal Research Reviews</u> , 20(1):1-27; <u>Wiley Interactive Science Journal</u> , Pub. online 12/22/99.
	AE	Virmani, M.A., "Protective actions of l-carnitine and acetyl-l-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors", <u>Pharmacological Research</u> , 32(6):383-389 (1995).

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	